These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 18064910)

  • 1. [The experimental models of Parkinson's disease in animals].
    Grigor'ian GA; Bazian AS
    Usp Fiziol Nauk; 2007; 38(4):80-8. PubMed ID: 18064910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic contributions to Parkinson's disease.
    Huang Y; Cheung L; Rowe D; Halliday G
    Brain Res Brain Res Rev; 2004 Aug; 46(1):44-70. PubMed ID: 15297154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controversies on new animal models of Parkinson's disease pro and con: the rotenone model of Parkinson's disease (PD).
    Schmidt WJ; Alam M
    J Neural Transm Suppl; 2006; (70):273-6. PubMed ID: 17017541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pigment epithelium derived factor (PEDF) is neuroprotective in two in vitro models of Parkinson's disease.
    Falk T; Zhang S; Sherman SJ
    Neurosci Lett; 2009 Jul; 458(2):49-52. PubMed ID: 19442875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosine hydroxylase-positive amacrine interneurons in the mouse retina are resistant against the application of various parkinsonian toxins.
    Nagel F; Bähr M; Dietz GP
    Brain Res Bull; 2009 Jun; 79(5):303-9. PubMed ID: 19406215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine-dependent neurodegeneration in Drosophila models of familial and sporadic Parkinson's disease.
    Bayersdorfer F; Voigt A; Schneuwly S; Botella JA
    Neurobiol Dis; 2010 Oct; 40(1):113-9. PubMed ID: 20211259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Animal models of Parkinson's disease.
    Jackson-Lewis V; Blesa J; Przedborski S
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S183-5. PubMed ID: 22166429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene-environment interactions in sporadic Parkinson's disease.
    Benmoyal-Segal L; Soreq H
    J Neurochem; 2006 Jun; 97(6):1740-55. PubMed ID: 16805780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Idiopathic Parkinson's disease: a review of clinical types and pathology.
    Olasode BJ
    Niger J Med; 2001; 10(3):116-20. PubMed ID: 11806009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
    Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
    Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [MPTP: a new chapter in the history of Parkinson's disease].
    Piccinin GL; Piccirilli M; Finali G; Stefano E
    Riv Neurol; 1989; 59(3):103-7. PubMed ID: 2688042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurotoxicant-induced animal models of Parkinson's disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration.
    Uversky VN
    Cell Tissue Res; 2004 Oct; 318(1):225-41. PubMed ID: 15258850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular models to investigate biochemical pathways in Parkinson's disease.
    Alberio T; Lopiano L; Fasano M
    FEBS J; 2012 Apr; 279(7):1146-55. PubMed ID: 22314200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The MPTP tale: pathway to prevention of Parkinson's disease?
    Williams A; Waring R
    Br J Hosp Med; 1993 May 19-Jun 1; 49(10):716-9. PubMed ID: 8324592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenesis of familial Parkinson's disease: new insights based on monogenic forms of Parkinson's disease.
    Hatano T; Kubo S; Sato S; Hattori N
    J Neurochem; 2009 Dec; 111(5):1075-93. PubMed ID: 19780902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Molecular genetics of Parkinson's disease].
    Shadrina MI; Slominskiĭ PA
    Genetika; 2006 Aug; 42(8):1045-59. PubMed ID: 17025154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alteration of dopaminergic markers in gastrointestinal tract of different rodent models of Parkinson's disease.
    Tian YM; Chen X; Luo DZ; Zhang XH; Xue H; Zheng LF; Yang N; Wang XM; Zhu JX
    Neuroscience; 2008 May; 153(3):634-44. PubMed ID: 18420351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular hydrogen is protective against 6-hydroxydopamine-induced nigrostriatal degeneration in a rat model of Parkinson's disease.
    Fu Y; Ito M; Fujita Y; Ito M; Ichihara M; Masuda A; Suzuki Y; Maesawa S; Kajita Y; Hirayama M; Ohsawa I; Ohta S; Ohno K
    Neurosci Lett; 2009 Apr; 453(2):81-5. PubMed ID: 19356598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 6-hydroxydopamine model: news from the past.
    Blandini F; Armentero MT; Martignoni E
    Parkinsonism Relat Disord; 2008; 14 Suppl 2():S124-9. PubMed ID: 18595767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Similarities and differences between MPTP-induced parkinsonsim and Parkinson's disease. Neuropathologic considerations.
    Forno LS; DeLanney LE; Irwin I; Langston JW
    Adv Neurol; 1993; 60():600-8. PubMed ID: 8380528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.